Kornimate/medical-research-clean huggingface dataset:
new information and communication technologies (ict´s) in basic life support training for non-medical students: educational trial

Conditions: Cardiac Arrest, Out-Of-Hospital

Summary: with the increase in life expectancy of the general population and advances in medicine, there is now a population with a higher amount of cardiovascular diseases that lead to an increased risk of sudden cardiac arrest. in most cases, this occurs in extra-hospital settings such as family homes, shopping centres, public transport and before people without any knowledge or training in basic life support. on the other hand, for every minute that passes without adequate attention of the victim, the probability of surviving or continuing to live with neurological severe sequelae decreases by 10%. in developed countries, public policies have been created to encourage basic life support education to the general population. in colombia, because of the high prevalence of these diseases and the need for public health strategies, a law was issued to provide access to automatic external defibrillators (aeds) in public places. however, it has not been developed strategies for education on this subject. for that reason, the investigators created an educational strategy of self-learning, which consists of a complete basic life support course based in new information and communication technologies with tools to manufacture a mannequin and a homemade dea, which will allow continuous training, with a very low cost compared to traditional life support training. the clinical trial will compare that two educational strategies, evaluating as primary aid, which approach has higher knowledge retention of life support chain at 6 months in students after the workshop. as secondary objectives, the investigators would evaluate the efficient in terms of response times, costs and student satisfaction. this study will be carried out in high school students from two different high schools, without prior training in life support. both strategies will be distributed randomly. the experimental group will carry out the self-learning strategy based on ict (information and communication technologies), with which they will be retrained every month, and the control group will carry out the conventional training only once as usual. subsequently, each of the objectives will be evaluated at six months. it is proposed that the self-learning strategy is superior compared to conventional training, requiring fewer resources to perform it and allows constant retraining, which improves retention and quality in a resuscitation process.


Eligibility criteria:
inclusion criteria: * senior students over 14 years in high school. exclusion criteria: * cognitive disorders. * cardiovascular o pulmonary diseases. * any condition that prevents physical activities. * to have any previous training in basic life support.

Keywords: cardiac arrest basic life support new information and communication technologies
hammock position and kangaroo care

Conditions: Infant Development; Premature

Summary: this study was planned to evaluate the effectiveness of two positions that may have an effect on pain, stress, comfort and physiological parameters in premature infants.

providing adequate therapeutic positioning in preterms can minimize postural abnormalities and asymmetries associated with prematurity and nicu stay, as well as support the development of spontaneous and functional motor abilities of infants. studies show that positioning directly affects cardiovascular, respiratory and sleep-wake states. when the literature is examined; although the vital signs, pain levels and comfort levels of babies in the nicu have been examined in many applications, the number of studies comparing the hammock position and kangaroo care in preterms is very limited. therefore, this study will try to determine the effect of hammock position and kangaroo care on the pain, stress, comfort and physiological parameters of the infants. it is thought that the study will provide new data to the literature and lead to many researches.

Eligibility criteria:
inclusion criteria: * infants having at least 2 days of inpatient treatment from, * infants 32-36+6. being born during the gestational week, * infants not receiving a medical diagnosis other than prematurity (serious respiratory, cardiological, endocrine and metabolic problems, hearing problems, hypoglycemia and sepsis), * apgar score above 6 at the 5th minute infants will included. exclusion criteria: * infants having at least 2 days of inpatient treatment from, * infants 32-36+6. being born during the gestational week, * infants not receiving a medical diagnosis other than prematurity (serious respiratory, cardiological, endocrine and metabolic problems, hearing problems, hypoglycemia and sepsis), * apgar score above 6 at the 5th minute infants will included.

Keywords: premature pain stress comfort
effects of concentric cycling training protocol during (neo)adjuvant chemotherapy in breast cancer patients: protect-07 study

Conditions: Breast Cancer

Summary: the association of anthracyclines (ant) and paclitaxel (tax) is one of the main treatments used in breast cancer. these treatments are known to induce severe side effects such as a decrease in overall exercise capacity (physical condition) in response to muscle and cardiorespiratory alterations. if exercise may be an effective preventive strategy, it seems important to prescribe the most efficient exercise modality. among them, concentric cycling (i.e., classic cycling) can significantly induce metabolic stimulus, which is needed for maintaining exercise capacity. the protect-07 study aims to demonstrate the superiority of a training program based on concentric cycling during chemotherapy compared to standard treatment. the duration of the training program is 15 weeks with one session per week.

there will be two groups of patients after drawing lots using a process called randomization. the probability is one in two of being in the group participating in the training program, the other group following the standard treatment.

Eligibility criteria:
inclusion criteria: * woman ≥ 18 years old * stage i to iii breast cancer * patient currently planning (neo)adjuvant treatment combining anthracycline-cyclophosphamide and weekly paclitaxel (± trastuzumab) * affiliation to a social security system * able to speak, read and understand french exclusion criteria: * no prior chemotherapy treatment * any known cardiac or vascular pathology * contraindications to physical fitness assessment * protected adult * psychiatric, musculoskeletal or neurological problems * pregnant or breastfeeding woman (nb: this population is already subject to a contraindication to (neo)adjuvant treatment. for women of childbearing age, a betahcg dosage is already carried out systematically before the start of chemotherapy and information on the need for contraception throughout the chemotherapy period is provided before the start of treatment. as part of this study, only the presence of this test with a negative result at the start of chemotherapy will be checked. inclusion, if available).
effects of improved calf muscle function on gait, balance and joint loading in older adults

Conditions: Osteoarthritis, Knee; Mobility Limitation; Accidental Fall

Summary: this study investigates the role of calf muscle function in gait performance, balance and knee joint loading. previous studies have linked age-related loss of calf muscle function with impairments in gait performance and balance, and increased loading of the areas of the knee joint that are susceptible to the development of osteoarthritis. in this study, an exercise intervention targeting structural and neural aspects of impaired calf muscle function with ageing is utilized. the intervention lasts 8 weeks and includes either biofeedback training using electromyography to alter muscle activation patterns or a combination of biofeedback training and strength training for the calf muscle to modify calf function during walking. the study will test whether the intervention improves walking speed, reduces the metabolic cost of walking, improves standing balance and reduces knee joint loading.


Eligibility criteria:
inclusion criteria: * age between 65 and 75 exclusion criteria: * dependent living status * not able to walk without an assistive device or for 30 min without stopping * diagnosed neurological disease or joint disorder and pain during walking * surgery on lower extremities * current musculoskeletal injury * previous cardiovascular event or symptoms during exercise (acute ecg change, coronary disease, symptomatic arrhythmia, symptomatic coronary stenosis, heart failure, myocarditis, pericarditis, pulmonary embolism, pulmonary infarct, artery bulge or rupture risk) * body mass index \ 35 kg/m2 * contraindications for magnetic resonance imaging * mini mental state examination score of 23 points and lower

Keywords: osteoarthritis knee achilles tendon triceps surae balance electromyography biofeedback strength training gait walking
performance and safety of use of the "kontact perio level" transgingival titanium dental implant

Conditions: Tooth Loss; Partially Edentulous Maxilla; Partially Edentulous Mandible

Summary: as part of post-marketing clinical follow-up, biotech dental sets up the collection and evaluation of clinical data proactively with the aim of confirming the safety, performance as well as the constantly acceptable nature of the risks identified and of detecting potential emerging risks with the use of "kontact perio level" implants in everyday practice.


Eligibility criteria:
inclusion criteria: * edentulous patient requiring the placement of one (or more) dental implant (s) in the maxilla or mandibular * age ≥ 18 years old * good general health (asa score between \[1-2\]) * sufficient volume and bone quality (with or without bone graft) to support the implant * non-objection of the patient for the collection of his medical data as part of the study exclusion criteria: * poor oral hygiene * bruxism, parafunctional habits, occlusion disorders and / or temporomandibular joints * infections and oral inflammation such as active periodontitis, active gingivitis * patient with metabolic disorders (eg diabetes mellitus) or bone disease that may compromise peri-implant tissue healing * heavy smoker (\> 10 cigarettes / day) * patient with a pathology or immunosuppressive therapy such as chemotherapy, radiotherapy * patient on prolonged steroid therapy * titanium / titanium alloy allergy * alcohol or drug abuse * pregnant woman (or likely to be pregnant); or breastfeeding * difficulty of medical follow-up patients with geographical, social or psychological constraints * persons deprived of liberty or guardianship * involuntary / patient refusal to participate in the study
diet and depression

Conditions: Depression; Major Depressive Disorder; Weight Gain; Obesity; Metabolic Syndrome

Summary: this study is a pilot open label crossover trial to assess the feasibility and acceptability of reducing ultra- processed foods (upf) in a personalized manner from the diets of patients with major depressive disorder who eat a large percentage of upf.

there is a need for additional treatment or augmentation strategies for people who have depression. epidemiological and observational studies show that an increased consumption of ultra-processed food (upf) is associated with an increased risk of developing depression. this study will test the hypothesis that that reducing upf intake from the diets of patients with major depressive disorder who eat a large percentage of upf is a feasible and acceptable intervention.

Eligibility criteria:
inclusion criteria: * 18-80 year olds (inclusive), all race/ethnic groups * willing to not change psychotropic medication or psychotherapy regimen during the study * willing and able to come to ucsf for in person visits two times * ability to speak and read english and answer participant surveys exclusion criteria: * psychiatric hospitalization in past 3 months * active suicidal ideation with intent and plan or scoring a 3 or higher on the columbia suicide severity rating scale (c-ssrs) * in a current severe mood state when entering the study that would prohibit compliance with study visits or dietary program * known gi abnormalities or known gi medical problems (diarrhea, chronic intestinal disease, toxic megacolon, ileum) or known swallowing or chewing disorders or issues * anticipating or planning any major changes in physical activity or sleep during the study * pregnant or planning to be pregnant during the study * breastfeeding or planning to breastfeed during the study

Keywords: ultra-processed food depression diet
a clinical study evaluating the safety and efficacy of bind19 treatment in r/r all and lymphoma subjects

Conditions: Relapsed B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed／Refractory B-cell Lymphoma

Summary: this is a single arm, open-label, uni-center, phase i/ii study to determine the safety and efficacy of an experimental therapy called bind19 cells in patients with b-cell acute lymphoblastic leukemia or lymphoma, who are chemo-refractory, relapsed after allogeneic sct, or are otherwise ineligible for allogeneic stem cell transplant.


Eligibility criteria:
inclusion criteria: * male and female subjects with cd19+ b cell malignancies in patients with no available curative treatment options (such as autologous or allogeneic sct) who have limited prognosis (several months to \< 2 year survival) with currently available therapies will be enrolled. * cd19+ leukemia or lymphoma * not eligible for allogeneic sct because of age, comorbid disease, or lack of available family member or unrelated donor * follicular lymphoma, previously identified as cd19+: * disease responding or stable after most recent therapy (chemotherapy, moab, etc) * ecog result is 0, 1 or 2. * with normal heart, liver and kidney functions. * negative serum antibody for ebv, cmv, hbv, hcv, hiv and syphilis. * negative in pregnancy test （female subject only). exclusion criteria: * ecog result is 3, 4 or 5. * pregnant or lactating women * uncontrolled active infection * active hepatitis b or hepatitis c infection * concurrent use of systemic steroids. recent or current use of inhaled steroids is not exclusionary * previously treatment with any gene therapy products * hiv infection * enrolled to other clinical study in the last 4 weeks. * subjects with systemic auto-immune disease or immunodeficiency. * subjects with cns diseases. * subjects with secondary tumors. * subjects with tumor infiltration in liver, brain or gi tract.
multicentric prospective validation of a universal test to quantify apixaban, rivaroxaban, danaparoid and fondaparinux levels

Conditions: Anticoagulation; Venous Thromboembolism; Atrial Fibrillation

Summary: despite their usefulness in perioperative and acute care settings, factor-xa inhibitors-specific assays are scarcely available, contrary to heparin anti-xa assay. the investigators aimed at assessing whether the widely used heparin anti-xa assay can quantify the apixaban, rivaroxaban, fondaparinux and danaparoid levels.


Eligibility criteria:
inclusion criteria : * blood sample from adult patients treated with apixaban or rivaroxaban or danaparoid or fondaparinux exclusion criteria : * patients treated with unfractionated heparin or low molecular weight heparin

Keywords: anticoagulants (mesh) blood coagulation tests (mesh) drug monitoring (mesh) factor xa inhibitors (mesh) heparin (mesh)
study of cep-701 in treatment of prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (psa) by day 85.

a serological psa response is defined as a reduction from baseline psa serum concentration of at least 50%, which is confirmed by a second psa value 28 or more days later.

Eligibility criteria:
inclusion criteria: * at least 18 yrs of age * diagnosis of adenocarcinoma of the prostate * no detectable metastatic disease as assessed by bone and ct scans * has increasing serum psa concentrations * life expectancy of at least 3 months * ecog of 0 or 1 * has been withdrawn from antiandrogen therapy for at least 6 weeks prior to entering screening period exclusion criteria: * has asymptomatic disease * has active gi ulceration or bleeding * has been treated with non-hormonal systemic anticancer therapy or has received radiation within 4 weeks of baseline visit * bilirubin \>2x uln or alt or ast \>2xuln or serum creatinine \>1.5mg/dl * hemoglobin \<9g/dl or platelets below 100,000/ul or anc below 1500/ul * receiving treatment for hiv with protease inhibitors * has had prior malignancy within past 5 yrs with exception of resected basal or squamous cell carcinomas of the skin * has used investigational drug with previous one month

Keywords: prostate cancer prostate specific antigen psa
evaluating safety and efficacy of autologous gene-edited muscle stem cells (genphsats-basket)

Conditions: LGMD

Summary: this study is an investigator initiated first-in-human interventional open label phase 1/2a clinical trial investigating an atmp in the orphan disease lgmd to evaluate safety and efficacy.

this trial is directed towards a first-in-human application of genphsats; gene edited primary human satellite cell derived muscle stem cells as a new advanced therapy medicinal product (atmp) in a phase 1/2a clinical trial with gene edited phsats (genphsats) initiating healthy muscle development in patients with lgdm. the trial is set up to verify if genphsats can provide an therapy option for lgdm patients as there is currently no therapy available. the genphsats are an autologous product comprised of primary human satellite cell derived muscle stem cells obtained from the patient's own muscle tissue and gene edited in vitro prior to transplantation.

Eligibility criteria:
inclusion criteria: * lgdm diagnosed, * identified gene defect location and gene editing proved feasible, * age ≥14 years, * patient in treatment in the department at charité, universitätsmedizin berlin, muscle research unit and outpatient clinic for muscle disorders, * signed informed consent exclusion criteria: * acute or chronic inflammatory local or systemic disease * coagulation disorder * known complications due to local anesthesia, * congenital heart defect, cardiac arrhythmia, * pathology of the airways such as micrognathia * pierre robin sequence * central hypoventilation syndrome/ondine syndrome * significant other medical or psychiatric illness * positive serology for hiv and/or hepatitis a, b, c * pregnant or lactating women * known allergic reaction to constituents of the cryopreservation medium
comparison between kinesiotaping and cold therapy after total knee arthroplasty

Conditions: Surgery

Summary: the investigators aim was to compare the effectiveness of kinesiotaping and cold therapy on muscle strength and functional performance outcomes in patients with tka during early postoperative period. one-hundred-eleven patents with tka are going to randomly assigned to control, kt and ct groups (nc=nkt=nct=37).

total knee arthroplasty (tka) has been established as a valuable procedure patients with end-stage osteoarthritis and the rates of elective tka are increasing steadily each year. ninety percent of patients reported reduced pain, improved functional ability, and greater health related quality of life after tka. kinesiotaping (kt), a type of elastic tape that is being increasingly used for the management of pain and oedema after surgery 1. . cold therapy (ct) can also help relieve pain and swelling during early postoperative period 2. . these two application may have impact on functional performance outcomes in patients with tka. the number of studies that include kt in the rehabilitation process is increasing, but there isn't any study that compare kt application and ct after tka. the aim was to compare the effectiveness of kinesiotaping and cold therapy on muscle strength and functional performance outcomes in patients with tka during early postoperative period. methods one-hundred-eleven patents with tka are going to randomly assigned to control, kt and ct groups (nc=nkt=nct=37). kt group are going to receive kt for lymphatic correction and rectus femoris facilitation technique. ct group are going to receive ct immediately after operation and following postoperative days. after surgery, all patients will receive standard post-operative treatment including continuous passive motion, active-assistive and active range of motion exercises, isometric and isotonic strengthening exercises, gait training and transfer training. after operation, pain intensity, active range of motion and knee function score \[hospital for special surgery (hss) score\] functional activities are going to evaluate using the iowa level of assistance scale, and walking speed was evaluated using the iowa ambulation velocity scale. isometric muscle strength measure of quadriceps femoris and hamstring muscles assessed by hand-held dynamometer. all measurements evaluated at the discharge. one way anova is going to be used in statistical analysis.

Eligibility criteria:
inclusion criteria: * 40 years older above * have a primary total knee arthroplasty exclusion criteria: * revision total knee arthroplasty * unable to understand verbal and written instructions * having previously orthopaedic or neurological disorder that causes gait disturbance and having surgery within six months.

Keywords: kinesiotaping cold therapy functional performance
artificial intelligence in the diagnosis of orthopaedic conditions, particularly bone tumours and infection

Conditions: Bone Tumours; Bone Infection; Prosthetic Joint Infection; Prosthetic Infection

Summary: translational research aimed at improving diagnostic accuracy of musculoskeletal infection and musculoskeletal tumours using machine learning applied to clinical data, histopathological sections and genomic sequencing.


Eligibility criteria:
inclusion criteria: suspected infection of bone tumour and biopsy taken for analysis exclusion criteria: patient doesn't consent
early management strategies of acute heart failure for patients with nstemi

Conditions: Early Management; Acute Heart Failure; NSTEMI - Non-ST Segment Elevation MI

Summary: there are always poor outcomes in patients with acute myocardial infarction(ami) combined with elevated bnp/nt-probnp level. an elevated bnp/nt-probnp level highly indicates acute heart failure(ahf).levosimendan is recommended in many clinical trials of heart failure and chinese heart failure guidelines. as a result, the investigators form a hypothesis that when patients with ami combined with elevated bnp/nt-probnp level are in conditions before ahf, to use levosimendan may reduces the risk of heart failure and improve the outcome.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with nstemi in outpatient service or admitted to hospital; 2. patients with an elevated nt-probnp level; 3. patients sign the informed consent; exclusion criteria: 1. patients with hypotension(systolic pressure\<100mmhg), creatinine clearance rate\<30ml/min or be allergic to levosimendan; 2. patients whose heart function grade of killip are level iii\~iv; 3. patients suffering from hepatic failure, renal failure or other diseases which may shorten the lifetime to 6 months(for example tumor); 4. patients with valvular heart diseases influencing haemodynamics, hypertrophic or restricted cardiomyopathy, constrictive pericarditis, severe pulmonary hypertension or myocarditis; 5. patients with serum potassium level\<3.5mmol/l; 6. pregnant and lactating women; 7. patients participating in other relevant clinical studies.